Institut Pasteur Korea – Hakim Djaballah, CEO
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
Institut Pasteur Korea is conceptualized around the virtual “genome to drugs” pipeline. The goal of IP-Korea is to actively implement post-genomic approaches into accelerated drug discovery. Accordingly, IP-Korea is situated at the very fault line between basic research and application.
The positioning of our institute is in good accordance with the Pasteurian tradition and mission. During its long history Institut Pasteur in Paris has been able to combine scientific achievements with their application in public health. This has improved the lives of millions of patients over the last 130 years, and has earned Institut Pasteur 10 Nobel prizes.
To extend and build on these achievements, IP-Korea is the first to develop a technology-based approach to therapeutic development in the areas of infectious and chronic diseases.
Strategically it combines its strength in biomedical research with Korean expertise in Information and Chemical technologies.
The result is the consequent implementation of visualization and imaging technology in analyzing disease models, accelerating both drug discovery and basic research.
Contact details
Address: 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Tel: +82 31 8018 8000
Fax: +82 31 8018 8010
Email: ipkorea@ip-korea.org
www.ip-korea.org
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
The French-Korean Chamber of Commerce and Industry (FKCCI) has grown rapidly in the last decade, both in terms of members and revenues. Its managing director, Stella Yoon, explains how the…
YongBum Choi, general manager of Ferring Korea, explains how he plans to foster the Ferring values in the local affiliate. Mr Choi also breaks down the stigmas associated with assisted…
The Pharmaceutical Strategy Institute (PSI) is a Korean consulting firm helping local biotech companies reach success by providing strategic and legal counsel all along the value chain. Its founder &…
James Jungkue Lee, founder and CEO of Bridge Biotherapeutics, explains his strategy for risk mitigation in running a virtual biotech start-up. He also offers his insights into the company’s partnership…
Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from the structure of Korea’s healthcare…
Quegen Biotech is a company focusing on manufacturing beta-glucan for use in a range of healthcare products, from hangover cures to oncology treatments. In this interview, Dr Jong Dae Lee…
Pil Soo Oh has been the managing director of Lundbeck Korea since the establishment of the affiliate in 2002. Mr Oh offers his insights into Lundbeck’s footprint in Korea, their…
Jong-Gu Chung, general manager of CooperVision Korea, lifts the lid on his strategy to establish their position in the Korean market for contact lenses. Chung also gives his assessment of…
Established in 1986, the KDRA is Korea’s leading new drug research and development special corporation, established under the Ministry of Science and ICT and composed of 350 members. Its executive…
LG Life Sciences is one the early pioneers of innovative drug development in Korea with a diversified portfolio of chemical drugs, vaccines, biosimilars, biologics, and dermo-cosmetics. Its president, Dr Son,…
South Korean heavyweight Daewoong Pharmaceutical saw record sales in 2018, but did see a decrease in its EBITDA figures. To ensure its future profitability, the company has decided to invest…
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
See our Cookie Privacy Policy Here
